Zipeprol: Preclinical assessment of abuse potential

Drug and Alcohol Dependence

Volumn 42, Issue 2, 1996, Pages 93-104

  Acteo, M D ^a   Bowman, E ^a   Butelman, E ^b   English, J A ^e   Harris, L ^a   Jacobson, A E ^d   Mattson, M V ^d   Medzihradsky, F ^b   Patrick, G ^a   Rowlett, J K ^e   Smith, C B ^b   Winger, G ^b   Woods, J H ^b,c   Woolverton, W L ^e  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

^d NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^e UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

Author keywords

Abuse potential; Opioid abuse; Piperazine; Zipeprol

Indexed keywords

AMPHETAMINE; ANTITUXIL 7; BALUTOX; CENTRAL STIMULANT AGENT; CPDD 0042; KAPPA OPIATE RECEPTOR; METHOHEXITAL; MORPHINE; MU OPIATE RECEPTOR; NIH 10843; OPIATE; PENTOBARBITAL; QUADAZOCINE; SIGMA OPIATE RECEPTOR; UNCLASSIFIED DRUG; ZIPEPROL;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CONVULSION; DRUG ABUSE; DRUG ACTIVITY; DRUG DEPENDENCE; DRUG DETERMINATION; DRUG DISCRIMINATION; DRUG RECEPTOR BINDING; DRUG WITHDRAWAL; FEMALE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; REINFORCEMENT; RHESUS MONKEY;

ANIMALIA; MACACA MULATTA; RODENTIA;

EID: 0030271197     PISSN: 03768716     EISSN: None     Source Type: Journal    
DOI: 10.1016/0376-8716(96)01267-7     Document Type: Article

References (39)

1. Aceto, M.D., Bowman, E.R., Harris, L.S. and May, E.L. (1994) Dependence studies of new compounds in the rhesus monkey, rat, and mouse (1993). In: Problems of Drug Dependence, 1993. NIDA Res. Monogr. 140, Vol. 1 (Harris, L.S., ed.), pp. 103-178. NIH Pub. No. 94-3748. Bethesda, Maryland.
2. 2 analysis. J. Pharmacol. Exp. Ther. 251, 455-460.
3. Butelman, E.R., Winger, G., Zernig, G. and Woods, J.H. (1995) Butorphanol: characterization of agonist and antagonist effects in rhesus monkeys. J. Pharmacol. Exp. Ther. 272, 845-853.
4. 50) of an enzymatic reaction. Biochem. Pharmacol. 22, 3099-3103.
5. Coughenour, L.L., McLean, J.R. and Parker, R.B. (1977) A new device for the rapid measurement of impaired motor function in mice. Pharmacol. Biochem. Behav. 6, 351-353.
6. Cosnier, D., Hache, J. Labrid, C. and Rispat, G. (1976) General pharmacological properties of a new non-opiate antilussive: zipeprol (3024 CERM). II. Actions on the cardiovascular system, intestinal transit and central nervous system. Arzneimittel-Forschung 26,848-855.
7. Crippa, O., Polettini, A. and Avato, F.M. (1990) Lethal poisoning by zipeprol in drug addicts. J. Forensic Sci. 35, 992-999.
8. de Costa, B.R., He, X.-S., Linders, J.T.M., Dominguez, C., Gu, Z.-Q., Williams, W. and Bowen, W.D. (1993) Synthesis and evaluation of conformationally restricted N-2-(3,4-dichlorophenyl)ethyl]-N-methyl-2-(1-pyrrolidinyl)ethylamines at σ receptors. 2. Piperazines, bicyclic amines, bridged bicyclic amines, and miscellaneous compounds. J. Med. Chem. 36, 2311-2320.
9. de Costa, B.R. and He, X.-S. (1994) Structure-activity relationships and evaluation of sigma receptor ligands (1976-present). In: Sigma Receptors (Itzhak, Y., ed.), pp. 45-111. Academic Press, New York.
10. Dykstra, L.A. and Woods, J.H. (1986) A tail withdrawal procedure for assessing analgesic activity in rhesus monkeys. J. Pharmacol, Meth. 15, 263-270.
11. Emmerson, P.J., Liu, M.-R., Woods, J.H. and Medzihradsky, F. (1994) Binding affinity and selectivity of opioids at mu, delta, and kappa receptors in monkey brain membranes. J. Pharmacol. Exp. Ther. 271, 1630-1637.
12. France, C.P., Medzihradsky, F. and Woods, J.H. (1994) Comparison of kappa opioids in rhesus monkeys: behavioral effects and receptor binding affinities. J. Pharmacol. Exp. Ther. 268, 47-57.
13. France, C.P. and Woods, J.H. Discriminative stimulus effects of naltrexone in morphine-treated rhesus monkeys. J. Pharmacol. Exp. Ther. 250:937-943, 1989.
14. France, C.P., Winger, G., Medzihradsky, F., Seggel, M.R., Rice, K.C. and Woods, J.H. (1991) Mirfentanil: pharmacological profile of a novel fentanyl derivative with opioid and nonopioid effects. J. Pharmacol. Exp. Ther. 258, 502-510.
15. Glennon, R.A., Smith, J.D., Ismaiel, A.M., El-Ashmawy, M., Battaglia, G. and Fischer, J.B. (1991) Identification and exploitation of the σ-opiate pharmacophore. J. Med. Chem. 34, 1094-1098.
16. Hellewell, S.B., Bruce, A., Feinstein, G., Orringer, J., Williams, W. and Bowen, W.D. (1994) Rat liver and kidney contain high densities of sigma-1 and sigma-2 receptors: characterization by ligand binding and photoaffinity labeling. Eur. J. Pharmacol. -Mol. Pharmacol. Sect. 268, 9-18.
17. Hollingsworth, E.G. and Patrick, G.A. (1985) Involvement of the serotonergic system in the prolongation of pentobarbital sleeping time produced by prostaglandin D2. Pharmacol., Biochem. Behav. 22, 365-370.
18. Jaffe, J.H. and Martin, W.R. (1991) Opioid analgesics and antagonists. In: The Pharmacological Basis of Therapeutics, Eighth Edition, (Gilman A.G., Rail, T.W., Nies, A.S. and Taylor, P., eds.), pp. 485-521. Pergamon Press, New York.
19. Janiri, L., Mannelli, P. Persico, A.M., Diodato, S. and Tempesta, E. (1991) Zipeprol is a newly abused antitussive with an opioid spectrum and hallucinogenic effects. Drug Alcohol Depend. 27, 121-125.
20. Marembert, A. and Morin, D. (1993) Addiction to zipeprol. Presse Med. 22, 550.
21. May, E.L., Aceto, M.D., Bowman, E.R., Bentley, C., Martin, B.R., Harris, L.S., Medzihradsky, F., Mattson, M.V. and Jacobson, A.E. (1994) Antipodal α-N-alkyl(methyl-decyl)-N-normetazocines (5,9α-dimethyl-2′-hydroxy-6,7-benzomorphans): In vitro and in vivo properties. J. Med. Chem. 37, 3408-3418.
22. Moroni, C., Cerchiari, E.L., Gasparini, M. and Rota, E. (1984) Overdosage of zipeprol, a non-opioid antitussive agent. Lancet 1(8367), 45.
23. Nader, M.A., Winger, G., Woods, J.H. and Woolverton, W.L. (1991) Discriminative and reinforcing effects of brotizolam in rhesus monkeys. Psychopharmacology 103, 166-171.
24. Perraro, F. and Beorchia, A. (1984) Convulsions and cerebral oedema associated with zipeprol abuse. Lancet 1(8367), 45-46.
25. Quirion, R., Bowen, W.D., Itzhak, Y., Junien, J.L., Musacchio, J.M., Rothman, R.B., Su, T.P., Tam., S.W. and Taylor, D.P. (1992) A proposal for the classification of sigma binding sites. Trends Pharmacol. Sci. 13, 85-86.
26. Quirion, R., Chicheportiche, R., Contreras, P.C., Johnson, K.M, Lodge, D., Tam, S.W., Woods, J.H. and Zukin, S.R. (1987) Classification and nomenclature of phencyclidine and sigma receptor sites. Trends Neurosci. 10, 444-446.
27. Rispat, G., Burgi, H., Cosnier, D., Duchene-Marullaz, P. and Streichenberger, G. (1976) General pharmacological properties of a new non-opiate antitussive: zipeprol (3024 CERM). I. Action on respiratory function and acute toxicity. Arzneimittel-Forschung 26, 523-530.
28. Slobodkin, D., Thompson, D., Levin, G. and Jesurun, C.A. (1992) Habituation to zipeprol hydrochloride during pregnancy. J. Subst. Abuse Treat. 9, 129-131.
29. Teiger, D.L. (1974) Induction of physical dependence on morphine, codeine and meperidine in the rat by continuous infusion. J. Pharmacol. Exp. Ther. 190, 408-415.
30. Tempesta, E., Janiri, L., Mamseli, P. Persico, A.M. and Diodato, S. (1990) Clinical reports on recent abuse of an antitussive. Br. J. Addict. 85, 815-816.
31. Thurkauf, A., Mattson, M.V., Richardson, S., Mirsadeghi, S., Ornstein, P.L., Harrison, Jr., E.A., Rice, K.C., Jacobson, A.E. and Monn, J.A. (1992) Analogues of the dioxolanes dexoxadrol and etoxadrol as potential phencyclidine-like agents. Synthesis and structure-activity relationships. J. Med. Chem. 35, 1323-1329.
32. Walker, J.M., Bowen, W.D., Walker, F.O., Matsumoto, R.R., de Costa, B. and Rice, K.C. (1990) Sigma-receptors-biology and function. Pharmacol. Rev. 42,355-402.
33. Winger, G., Palmer, R.K. and Woods, J.H. (1989) Drug-reinforced responding: rapid determination of dose-response functions. Drug Alcohol Depend. 24,135-142.
34. Winger, G., Skjoldager, P. and Woods, J.H. (1992) Effects of buprenorphine and other opioid agonists and antagonists on alfentanil-and cocaine-reinforced responding in rhesus monkeys. J. Pharmacol. Exp. Ther. 261, 311-317.
35. Woods, J.H., France, C.P., Medzihradsky, F., Smith, C.B. and Winger, G.D. (1994) Evaluation of new compounds for opioid activity: Annual Report, 1993. In: Problems of Drug Dependence, 1993. NIDA Res. Monogr. 140, Vol. 1 (Harris, L.S., ed.), pp. 196-247. NIH Pub. No. 94-3748. Bethesda, Maryland.
36. Woolverton, W.L., Massey, B.W., Winger, G., Patrick, G.A. and Harris, L.S. Evaluation of the abuse liability of aminorex. Drug. Alcohol Depend. 36, 157-192.
37. Yoo, Y., Chung, H., Kim, E. and Kim, M. (1994) Postmortem distribution of zipeprol. J. Anal. Toxicol. 18, 213-216.
38. Yutrzenka, G.J., Patrick, G.A. and Rosenberger, W. (1985) Continuous intraperitoneal infusion of pentobarbital: a model of barbiturate dependence in the rat. J. Pharmacol. Exp. Ther. 232, 111-118.
39. Zernig, G., Butelman, E.R., Lewis, J.W., Walker, E.A. and Woods, J.H. (1994) In vivo determination of mu opioid receptor turnover in rhesus monkeys after irreversible blockade with clocinnamox. J. Pharmacol. Exp. Ther. 269, 57-65.